Benzinga | Dec 15, 2021 07:44AM EST

Wipro Introduced Regulatory Literature Monitoring for Pharmaceutical Organizations

Wipro Limited (NYSE:WIT), a leading global information technology, consulting and business process services company, has introduced regulatory literature monitoring for pharmaceutical organizations by entering a managed services engagement with Springer Nature.

Drug safety, referred to as Pharmacovigilance (PV), constitutes the detection, collection, prevention, and monitoring of negative effects that may occur because of the use of pharmaceutical products and other drugs. PV departments in Life Sciences organizations, to fulfil drug safety requirements, leverage literature monitoring that includes Annual Reports, Periodic Safety Update Reports, Individual Case Study Report (ICSR) Monitoring, among others.

Matthias Wissel, CEO, Springer Nature Technology and Publishing Solutions, said, "The pharmacovigilance industry has been rapidly growing over the years and the recent COVID-19 pandemic and vaccine development efforts have only augmented the need for more efficient pharmacovigilance practices. I am confident that the transition of our ADIS Pharmacovigilance business to Wipro Limited will enhance their collective capabilities and provide colleagues with new opportunities. Additionally, Wipro's domain expertise and investment in innovative and progressive platforms, such as TaloSafe and other new technologies, will further strengthen customer relationships, both existing and new."

Krishna Nacha, Senior Vice President, Head of Global Business Services and Enterprise Transformation, iCORE, Wipro Ltd., said, "Over the past 18 months, increased patient safety has become paramount the world over. Organisations working with Wipro, a leader in the PV space, will benefit from ICSR literature services that have been developed over 15 years to a client base that includes 19 global Life Sciences companies."

TaloSafe enables organizations to automate end-to-end PV processes and represents expertise developed by Wipro in the Life Sciences space over the past decade.